What happened
Chinese pharmaceutical firms CSPC Pharmaceutical, RemeGen, and Haisco Pharmaceutical Group recently secured significant out-licensing deals, collectively valued over $24.8 billion. CSPC's agreement reached up to $18.5 billion, RemeGen's deal with AbbVie for its RC148 antibody drug was worth up to $5.6 billion, and Haisco granted AbbVie rights to pain drug molecules for up to $745 million. These transactions signal a strategic shift within China's biotech sector, moving from low-cost manufacturing towards high-value innovation, with artificial intelligence reshaping drug discovery.
Why it matters
High-value out-licensing deals, especially AI-driven ones, intensify global competition for novel therapeutics. R&D leaders and procurement teams must reassess pipelines and partnership strategies, recognising China's growing capacity for innovative drug development. Chinese firms use advanced R&D and AI to generate valuable intellectual property, attracting investment from global pharmaceutical giants. This trend indicates future access to early-stage drug candidates will increasingly originate from diverse global sources, demanding agile evaluation and integration capabilities.
